Celyad Oncology SA reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was EUR 26.51 million compared to EUR 17.2 million a year ago. Basic loss per share from continuing operations was EUR 1.7 compared to EUR 1.23 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3035 EUR | -1.30% | -6.62% | -22.18% |
04/04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
09/02 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.18% | 13.73M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021